Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

continue to focus our efforts on preparing for a successful transition to a clinical-stage company and remain on track to nominate our second microRNA candidate for clinical development by the end of the year.  Our recent progress is encouraging and we look forward to realizing the potential that our microRNA technology may have in transforming the field of drug discovery."

Neil W. Gibson , Ph.D., Chief Scientific Officer, added, "We believe that RG-101 is a novel, pan-genotypic agent that may play an important role in future HCV therapy. We are very encouraged by the pre-clinical data seen to date, which includes activity against some of the known mutations that lead to resistance to the current HCV therapies and a favorable potency and PK profile which supports a once-a-month dosing paradigm.  We believe that RG-101 may be useful in difficult-to-treat HCV patients in combination with existing and emerging therapies and we look forward to exploring its clinical utility."

Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President of Finance, said, "As we prepare for clinical activity with RG-101, Regulus continues to maintain a strong financial position with over $90 million in cash at quarter-end. We remain on track to achieve our stated goals of finishing 2013 with at least $60 million in cash, while maintaining a burn rate of approximately $30 million to $35 million."

Recent Highlight

  • Selected New Opportunity in Oncology.  Regulus also announced today that it has selected microRNA-221 (miR-221) as an attractive target for potential clinical evaluation in patients with hepatocellular carcinoma (HCC).  Regulus is currently conducting target validation activities and expects to report further progress on this opportunity in the second half of 2013.
  • First Quarter 2013 Financial Results & Highlights Regulus reported a net loss o
    '/>"/>

    SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    3. Regulus to Present at Future Leaders in the Biotech Industry Conference
    4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    7. Regulus to Present at Two Upcoming Investor Conferences
    8. Regulus Appoints Mark G. Foletta to its Board of Directors
    9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
    10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
    (Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
    (Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
    Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
    ... 25, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... John H. Johnson as Chief Executive Officer, effective January 31, ... Savient,s board of directors. Mr. Johnson brings significant ... a Senior Vice President of Eli Lilly and Company and ...
    ... recently launched eCS Inpatient EHR V1.2 (eCS), the first ... medium hospitals. eCS,s uniqueness is the tight linkage of ... a single web-based software solution. The solution is offered ... simplified deployment. "eCS is an affordable solution ...
    Cached Medicine Technology:Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals 2
    (Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
    (Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
    (Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
    (Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
    (Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
    Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
    ... of New England and the Rhode Island House and senate ... multiple sclerosis, AIDS and other chronic // diseases ... these patients. The new bill allows patients to have possession ... marijuana was illegal. But, the Governor Carcieri still oppose the ...
    ... has a counter which states that heart conditions became worse ... heart disease when they were fed a soy diet. ... mice carried and were severely affected by the soy diet. ... failure. This study was done by University of Colorado at ...
    ... a pilot study by The New Women's Health Initiative ... fat but rich in carbohydrates results in negligible weight ... between weight alterations in postmenopausal women Vis a Vis ... in this category were advised to reduce the fat ...
    ... was misled about the dangers of taking cannabis when the ... than a year ago, the British Home Secretary admits today. ... decision taken by his predecessor, David Blunkett, Charles Clarke said ... link between cannabis and mental illness. He made these damning ...
    ... in the offing for abdominal aortic aneurysm, a blood vessel condition ... ,This condition, a swelling // in the ... bursts, accounts for 1.36% of deaths in men over 65 in ... for men in that age group, Pulse magazine says. ...
    ... customers to trap doctors who conduct sex determination tests for ... State’s sex ratio is less than 800 females for every ... would be paid up to Rs.5,000 to help nab diagnostic ... Family Welfare Secretary D.S. Guru said field officers of the ...
    Cached Medicine News:Health News:UK public misled over downgrading cannabis: Govt 2Health News:Experts urging artery screening in the UK 2
    ... Supplemental Confirmatory (Western Blot): The assay uses ... on their surface. The cells are fixed ... slide. Fixed, uninfected T-cells are provided as ... sample with HIV- I antibodies comes in ...
    Bi-phasic peristaltic infusion pump for tumescent work....
    ... The Klein Pump provides ... requiring tumescent infiltration. Operates on ... off switch with safety Interlock ... Single Spike Tubing, Double Spike ...
    ... state of the art Aspirator offers ... It can accommodate up to 5 ... eliminating time consuming canister changes. The ... powerful performance with minimal noise. It ...
    Medicine Products: